Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysisMeta-Analysis Published on 2023-02-012023-07-08 Journal: Infection [Category] COVID19(2023년), [키워드] antibody convalescent plasma monoclonal antibody Network meta-analysis SARS-CoV-2. [DOI] 10.1007/s15010-022-01825-8 PMC 바로가기 [Article Type] Meta-Analysis
Potential of high-titre IgA convalescent plasma to improve survival and symptoms in COVID-19 patientsArticle Published on 2023-02-012023-07-10 Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), [키워드] antibodies convalescent plasma COVID-19 IgA transfusion. [DOI] 10.1111/eci.13928 PMC 바로가기
The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in miceArticle Published on 2023-01-172023-07-11 Journal: Cell Reports Medicine [Category] COVID19(2023년), [키워드] ADCC convalescent plasma COVID-19 Fc-effector IgA IgG IgM macrophages neutrophils. SARS-CoV-2 [DOI] 10.1016/j.xcrm.2022.100893 PMC 바로가기
Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk PatientsArticle Published on 2022-12-302023-07-11 Journal: Viruses [Category] COVID19(2023년), [키워드] convalescent plasma coronavirus disease 19 monoclonal antibody treatment. SARS-CoV-2 [DOI] 10.3390/v15010119 PMC 바로가기
Selection of plasma donors for the production of anti-SARS-CoV-2 immunoglobulin-based therapies: Strategies for quantitative antibody measurementsArticle Published on 2022-12-012023-07-10 Journal: Transfusion and apheresis science : official journ [Category] COVID19(2023년), [키워드] convalescent plasma donation immunoglobulins Neutralizing antibodies SARS-CoV-2. [DOI] 10.1016/j.transci.2022.103513 PMC 바로가기
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective studyMulticenter Study Published on 2022-12-012023-07-10 Journal: Hematological oncology [Category] COVID19(2023년), [키워드] convalescent plasma COVID-19 disease severity Hematological malignancy survival data. [DOI] 10.1002/hon.3060 PMC 바로가기 [Article Type] Multicenter Study
Identification of virus-specific B-cell epitopes by convalescent plasma from COVID-19 patientsArticle Published on 2022-12-012023-07-10 Journal: Molecular immunology [Category] COVID19(2023년), [키워드] B-cell epitopes convalescent plasma COVID-19 Neutralizing antibodies SARS-CoV-2. [DOI] 10.1016/j.molimm.2022.10.016 PMC 바로가기
Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapyRandomized Controlled Trial Published on 2022-11-152023-07-10 Journal: Cell Reports Medicine [Category] COVID19(2023년), [키워드] antibody Fc glycosylation convalescent plasma COVID immunomodulation COVID-19 Fc effector functions functional antibodies immunodominance shift nucleocapsid SARS-CoV-2 systems serology. [DOI] 10.1016/j.xcrm.2022.100811 PMC 바로가기 [Article Type] Randomized Controlled Trial
Phase II/III trial of hyperimmune anti-COVID-19 intravenous immunoglobulin (C-IVIG) therapy in severe COVID-19 patients: study protocol for a randomized controlled trialArticle Published on 2022-11-082022-11-16 Journal: Trials [Category] SARS, 변종, [키워드] adaptive anti-COVID-19 IVIG antivirals clinical evidence clinical trial collected convalescent convalescent plasma COVID-19 cumulative death Efficacy eligibility criteria evaluate Health hyperimmune immunization immunomodulators intravenous Intravenous immunoglobulin low dose monoclonal antibodies Neutralizing non-specific novel Novel coronavirus outcome Passive passive immunization Patient phase Pneumonia polyclonal polyclonal antibodies Pooled convalescent plasma Potential treatment Randomized Randomized controlled trial receive Recovered COVID-19 patients reported SARS CoV-2 SARS CoV-2. SARS-CoV-2 sealed Secondary outcomes severe COVID-19 severe COVID-19 patient severe COVID-19 patients Standard of care Steroids Study protocol therapeutic option therapy treat Treatment Trial variant variants of concern virus virus particles World Health Organization [DOI] 10.1186/s13063-022-06860-2 PMC 바로가기
Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trialArticle Published on 2022-11-012022-11-15 Journal: Intensive care medicine [Category] Fulltext, MERS, 바이오마커, [키워드] ABO-compatible convalescent plasma Adaptive platform trial Adults analysis assigned Biomarker Biomarkers chemokines community-acquired pneumonia convalescent plasma Convalescent plasma therapy coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient Critically ill critically ill patients Cytokines difference effector immune responses elevated endothelial explain heterogeneous homogeneous Hypothesis immunologically immunotherapies Inflammation IQR median multifactorial organ support outcome outcomes patients Population precision medicine Prevalence Randomized randomized clinical trial RCT RCTs REMAP-CAP reported secondary analysis Subphenotypes. tested therapy treatment effect Treatment response usual care with COVID-19 [DOI] 10.1007/s00134-022-06869-w PMC 바로가기